NANOG and cervical cancer: One of the significant results in this investigation is a considerable reduction in the stemness characteristic and colony formation of CaSki cancerous cells following therapy with E6-siRNA and Oxaliplatin and consequently plummet in the expression of stemness genes, such as CD133, CD44, and Nanog. CD133 has been the first potential cancer stem cells (CSC) marker in human cervical cancer, and also it has been reported that the CD44 marker plays a critical role in enriching the cervical CSC population [23].